<DOC>
	<DOCNO>NCT01614665</DOCNO>
	<brief_summary>The purpose study compare body absorbs process two different formulation anti-rejection medication tacrolimus ( Advagraf® Prograf® ) child receive organ transplant , safe effective long period time . This study child less 16 year old . No minimum age set , however , include study participant must able swallow medication capsule intact .</brief_summary>
	<brief_title>A Study Compare How Body Absorbs Processes Two Different Formulations Anti-rejection Medication Tacrolimus ( Advagraf® Prograf® ) Children Receiving Organ Transplant , How Safe Effective They Are Over Longer Period Time</brief_title>
	<detailed_description>Subjects undergoing primary heart , kidney liver transplantation meeting Inclusion Criteria comply Exclusion Criteria prior initiation tacrolimus therapy enrol . Subjects randomize treatment either Advagraf® Prograf® . The randomization 1:1 basis stratify organ centre . The study divide two part : Part A : The initial pharmacokinetic part study . Part B : A long term follow-up one year . The main objective Part A study collect PK data follow administration Advagraf® Prograf® de novo pediatric allograft recipient . Part B allow comparison safety efficacy profile Advagraf® vs. Prograf® long term ( 52 week ) post allograft transplantation . Part C : Continuation long-term follow-up ( Day 365 onwards ) . Patients complete Part B continue treatment Advagraf® currently available , offer participation continuation long-term follow-up Part C. Part C continue Advagraf® becomes available patient patient ' discontinuation , whichever early . This apply patient follow country : Czech Republic , Italy Poland .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>The subject age &lt; 16 year age , undergo primary liver , kidney heart allograft transplantation The subject must able swallow intact Prograf® Advagraf® capsule Subjects , treat since transplantation Basiliximab ATG/ Mycophenolate Mofetil ( MMF ) /steroids , whose gastric motility resume whose renal function adequate Day 1 ( Heart ) Subject receive multiorgan transplant previously receive organ transplant ( include retransplantation ) Subject pulmonary vascular resistance ≥4 Wood unit despite medication Subject significant renal impairment , define serum creatinine ≥230 μmol/l ( ≥2.6 mg/dl ) pretransplantation . ( Not applicable renal transplant subject ) Subject significant liver disease , define continuously elevate SGPT/ALT and/or SGOT/AST and/or total bilirubin level ≥3 time upper value normal range investigational site past 28 day . ( Not applicable liver transplanted subject ) Subject malignancy history malignancy within last 5 year , exception basalioma squamous cell carcinoma skin treat successfully . ( Not applicable transplanted subject primary organ diagnosis cancer ) Subject require systemic immunosuppressive medication indication transplantation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Transplant</keyword>
	<keyword>Prograf</keyword>
	<keyword>Heart</keyword>
	<keyword>Advagraf</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Kidney</keyword>
	<keyword>Liver</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Pediatric</keyword>
</DOC>